Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

Recruitment Status
RECRUITING
(See Contacts and Locations)Verified January 2026 by Medical College of Wisconsin
Sponsor
Medical College of Wisconsin
Information Provided by (Responsible Party)
Michelle Mitchell
Clinicaltrials.gov Identifier
NCT06494072
Other Study ID Numbers:
PRO00046965
First Submitted
July 1, 2024
First Posted
July 9, 2024
Last Update Posted
March 1, 2026
Last Verified
January 2026

ClinicalTrials.gov processed this data on February 2026Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

This is an open label, randomized, non-inferiority clinical trial to determine if a 5-day antibiotic course works as well compared to a standard antibiotic course (usually 7-10 days of antibiotics) in hospitalized children who are aged 3 months to less than 18 years old, with uncomplicated community acquired pneumonia.

We will recruit 150 participants meeting inclusion/exclusion criteria. Participants will be randomized to one of the study groups. In the experimental group, the participant will receive a total antibiotic course of 5 days. In the other group (control group), participants will receive the standard-of-care antibiotic course (the duration will be decided by the primary treating physician in this group). The selection of antibiotic therapy will be made by the treating physician, generally in accordance with the institutional clinical practice guideline on community acquired pneumonia, prior to enrollment in the study. Other medical care, aside from the treatment duration, will be the same and will be guided by the primary treating doctor. The primary treating doctor will also decide when the participant is medically ready for discharge from the hospital.

During the consenting process, a member of the research team will verify the contact numbers or email of the parent(s)/guardian of participant to be used after discharge for follow-up communication. Every participant's parent/guardian will receive a text message/email questionnaire on day 5 and day 14 after the start of antibiotics to assess for clinical improvement, side effect(s) to the antibiotics, recurrence of fever, or need for additional antibiotics or other medical care. Participants parent(s)/guardian will be contacted by phone for additional information if there is concern for a failure or significant medical concern.

The primary objective of this study is to compare the failure rate between a short course (5-days) and standard antibiotic course (usually 7-10 days of antibiotics) of antibiotics in hospitalized children with uncomplicated pneumonia. Failure will be defined as the clinical need for additional antibiotic treatment, emergency department visit or readmission to the hospital for a suspected lower respiratory tract infection within 14 days of treatment initiation.

The secondary objective will compare the rate of adverse drug events between short and long-course durations of antibiotic therapy in children hospitalized for CAP. Adverse drug events include any allergic reaction such as skin rash, itching or other and/or abdominal symptoms such as vomiting, stomach pain and diarrhea.

Data will be summarized by n (%) or mean and standard deviation (SD) or median and interquartile range (IQR). Continuous variables will be compared by t-test while categorical variables will be compared by Chi-square or Fisher's exact test. A 95% CI will be calculated for the difference in failure rate between the shorter antibiotic course (5-day) group and the standard course group. Non-inferiority will be declared if the 95% CI lies below 10%. P\<0.05 will be considered statistically significant. Data will be analyzed by SAS version 9.4 (SAS Institute Inc., Cary, NC) and SPSS version 28.0 (IBM Corp., Armonk, NY).

Condition or DiseaseIntervention/Treatment
Community Acquired Pneumonia in Children
Drug: Ampicillin for InjectionDrug: Ampicillin for Injection

Study Design

Study TypeInterventional
Actual Enrollment236 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingNone (Open Label)
Primary PurposeTreatment
Official TitleShort Versus Standard of Care Antibiotic Duration for Hospitalized Children With Uncomplicated Community-acquired Pneumonia: a Non-inferiority, Randomized Controlled Trial.
Study Start DateAugust 21, 2024
Actual Primary Completion Date1yr 11mos from now
Actual Study Completion Date1yr 11mos from now

Groups and Cohorts

Group/CohortIntervention/Treatment
Short course antibiotic duration
The participants in this group will receive a total antibiotic course of 5 days including the number of days received during their hospital admission and following hospital admission combined.
Drug: Ampicillin for Injection
Ampicillin is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
Standard of care antibiotic duration
Participants will receive the standard-of-care antibiotic course in this group. That is, the duration of antibiotics will be decided by the primary treating physician in this group. The antibiotic course will include the number of days received during the participant's hospital admission and following hospital admission combined.
Drug: Ampicillin for Injection
Ampicillin is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.

Outcome Measures

Primary Outcome Measures
  1. Treatment failure rate
    Treatment failure is defined as the clinical need for additional antibiotic treatment, an emergency department (ED) visit, or readmission to the hospital for a suspected lower respiratory tract infection within 14 days of treatment initiation.
Secondary Outcome Measures
  1. Adverse drug event rate
    Adverse drug events include allergic reactions, skin rash, abdominal symptoms (such as vomiting, stomach pain, or diarrhea), or other plausible associated complaints described by the parent(s)/guardian.

Eligibility Criteria

Ages Eligible for Study(Child, Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
Inclusion Criteria (ALL of the following must be met): 1. Children aged 3 months to \<18 years old 2. Hospitalized in either the acute care or the pediatric intensive care units 3. Clinically diagnosed with uncomplicated bacterial community acquired pneumonia (as determined by the treating physician) 4. Radiological findings suggestive of pneumonia (such as consolidation, lobar or interstitial infiltrates) 5. Achieved clinical stability within 72 hours from the first antibiotic dose (clinical stability includes being off supplemental oxygen/ventilatory support and temperature remaining \< 38 Celsius).
Exclusion Criteria
Inclusion Criteria (ALL of the following must be met): 1. Children aged 3 months to \<18 years old 2. Hospitalized in either the acute care or the pediatric intensive care units 3. Clinically diagnosed with uncomplicated bacterial community acquired pneumonia (as determined by the treating physician) 4. Radiological findings suggestive of pneumonia (such as consolidation, lobar or interstitial infiltrates) 5. Achieved clinical stability within 72 hours from the first antibiotic dose (clinical stability includes being off supplemental oxygen/ventilatory support and temperature remaining \< 38 Celsius). Exclusion Criteria (presence of ANY of the following will exclude a potential participant): 1. Hemodynamic instability at any point during hospitalization that required inotropic support 2. Requirement of respiratory support \> 72 hours 3. Presence of a parapneumonic effusion \>10 mm on decubitus x-ray or greater than ¼ of hemithorax opacified on chest imaging 4. Need for chest tube placement 5. Extrapulmonary involvement (ie: another infection located outside of the lungs) except for otitis media if the planned treatment is ≤ 5 days 6. Pneumonia caused by known staphylococcus aureus identified from culture (blood, bronchoalveolar aspirate, tracheal aspirate, or pleural fluid) 7. Antibiotic course started \>72 hours after admission 8. Antibiotics used for \> 24 hours within the 2 weeks prior to admission 9. Chronic respiratory illness other than asthma or reactive airway disease 10. Immunocompromised patient (primary or secondary) 11. Primary physician refusal 12. Parent refusal 13. Non-English speakers 14. Pregnant or lactating female 15. Participant will become ≥ 18 years old at or before the time of day 14 follow up 16. Inability to adhere to follow up

Contacts and Locations

Sponsors and CollaboratorsMedical College of Wisconsin
Locations
Childrens Wisconsin | Milwaukee Wisconsin, United States, 53226
Investigators
Principal Investigator: Michelle Mitchell, Medical College of Wisconsin